Fate’s killer memory

Fate Therapeutics Inc. has published the cell culture methodology behind Fate-NK100, its adoptive memory NK cell therapy in Phase I testing for cancer, and created two off-the-shelf versions of the candidate using iPS cells.

According to Jeffrey Miller, an academic collaborator on Fate’s NK cell programs, the key to Fate’s approach is its ability to isolate and expand subsets of NK cells with enhanced anticancer activity and prolonged lifespan in vivo compared with the general NK cell population. “The game changer in the NK field is the identification of an NK cell population in people with prior CMV exposure.”...